Pneumocystis jirovecii Pneumonia in Patients with Lung Cancer: A Review.
10.3779/j.issn.1009-3419.2022.101.14
- Author:
Ting LI
1
;
Jianying ZHOU
1
;
Qing WANG
1
Author Information
1. Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China.
- Publication Type:Review
- Keywords:
Chemoradiotherapy;
Immune checkpoint inhibitors;
Lung neoplasms;
Pneumocystis jirovecii pneumonia;
Risk factors
- MeSH:
Humans;
Incidence;
Lung Neoplasms/complications*;
Pneumocystis carinii;
Pneumonia, Pneumocystis/diagnosis*;
Risk Factors
- From:
Chinese Journal of Lung Cancer
2022;25(4):272-277
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the widespread use of immunodepressant agents, Pneumocystis jirovecii pneumonia (PJP) has been significantly found in non-human immunodeficiency virus (HIV) patients, such as those with malignancies, post-transplantation and autoimmune diseases. Although the risk factors and management of PJP have been extensively studied in the hematologic tumor and post-transplant populations, the research on real tumor cases is insufficient. Lung cancer has been the most common tumor with the highest number of incidence and death worldwide, and the prognosis of lung cancer patients infected with PJP is poor in clinical practice. By reviewing the previous studies, this paper summarized the epidemiology and clinical manifestations of PJP in lung cancer patients, the risk factors and possible mechanisms of PJP infection in lung cancer patients, diagnosis and prevention, and other research progresses to provide reference for clinical application.
.
